Moreover, considering that MS-444 is successfully used to inhibit HuR activity in cancer cells [33, 40, 104, 105] as well as in cystic fibrosis [39] and immune pathologies [106] and clinical trials involving HuR inhibitors are already underway [30], our preclinical results provide a strong rationale for further investigations to determine the true therapeutic benefit of HuR inhibition in mitigating cardiac dysfunctions in DMD patients. This evidence concerns the gene ELAVL1 and cancer.